US technology firm Fuse Science has entered the health and nutrition field for the first time after agreeing licensing agreement with macular degeneration nutritional supplements manufacturer Macular Health.
Fuse Science said that it had agreed the partnership to develop supplements that slow down the effects of Age-Related Macular Degeneration (AMD). Each year, 1.2 million of the estimated 12 million people afflicted with AMD will suffer severe central vision loss.
Macular Health’s AMD formula is designed to provide both short-term and long-term retinal improvement. Recent Multifocal Electroretinogram studies conducted at the UAB Callahan Eye Foundation Hospital in Birmingham, Alabama reported a 16% improvement in retina function after taking the supplement for 12 weeks and a 17% boost after taking the product for two years.
As part of the agreement, Fuse Science will provide limited license of its proprietary delivery technology to Macular Health. The proprietary delivery technology is planned to enhance how patients receive medicines and other nutritional supplements in a few concentrated liquid drops compared to traditional oral pills that must be swallowed.
In return, Macular Health will have access to Fuse Technology to develop new formulations.
"We believe that this relationship with Macular Health - in a multi-million dollar product category - represents a game-changing moment in how people can receive nutritional products and demonstrates just how broadly our technology could be used,” said Brian Tuffin, Fuse Technology’s chief executive.
“We see this as the first of several major licensing opportunities."
"Fuse Science and their expert team of scientists will help us advance the treatment for millions of people afflicted with the leading cause of blindness in the United States," said Jeffery McAnnally, Macular Health's chief executive.
"We believe this partnership will change the way patients take and use our current and future products."